NASDAQ$OCGN
Ocugen Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Ocugen experienced a transformational year with significant progress across its portfolio, including the lifting of the clinical hold for COVAXIN™ and advancements in gene therapy clinical development.
Ocugen reported fourth quarter and full year 2021 financial results, highlighting the lifting of the clinical hold for COVAXIN™, progress in pediatric EUA submission, initiation of a Phase 1/2 clinical trial for OCU400, and a public offering of common stock.
- FDA lifted clinical hold on IND application for COVAXIN™, clearing the way for Phase 2/3 clinical trial.
- Engagement with FDA to advance pediatric EUA for COVAXIN™ included submission of safety data and neutralization data against Omicron.
- Comprehensive responses regarding COVAXIN™ submitted to Health Canada for the NOD.
- OCU400 Phase 1/2 clinical trial initiated for the treatment of inherited retinal diseases.
Headline financials
Revenue & EPS history
Ocugen · Revenue · Quarterly
$1.53M
Forward guidance
Ocugen is poised for another great year in 2022, with plans to commence clinical trials and provide periodic updates.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
-1.2%
Avg return
Earnings day
-2.7%
Avg return
5 days after
-3.7%
Avg return
30 days after
42%
19 / 45 earnings
Positive
+31.5%
Q1 2016
Best reaction
-27.5%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.0% | +1.0% | -12.0% | |
| Q4 2025 | +5.4% | -10.8% | -3.8% | |
| Q3 2025 | -1.4% | -5.6% | -14.7% | |
| Q1 2025 | -2.3% | +0.9% | +53.8% | |
| Q4 2024 | -2.8% | -5.8% | +12.2% | |
| Q3 2024 | -0.9% | -11.3% | -19.4% | |
| Q2 2024 | +5.9% | +11.9% | -3.4% | |
| Q1 2024 | +8.3% | +5.5% | -16.0% | |
| Q4 2023 | -9.4% | -17.0% | +24.5% | |
| Q3 2023 | -6.3% | -2.6% | +1.3% | |
| Q2 2023 | -8.8% | +3.4% | -10.4% | |
| Q1 2023 | +3.3% | +7.3% | -32.1% | |
| Q4 2022 | +2.3% | +6.6% | -15.6% | |
| Q3 2022 | -3.3% | +15.7% | -8.5% | |
| Q2 2022 | +2.9% | +2.2% | -13.4% | |
| Q1 2022 | -12.3% | -19.7% | +0.4% | |
| Q4 2021 | +15.0% | +14.9% | +13.9% | |
| Q3 2021 | -11.4% | -8.4% | -41.3% | |
| Q2 2021 | +8.4% | +5.2% | -0.8% | |
| Q1 2021 | +6.2% | -10.1% | -9.0% | |
| Q4 2020 | -6.6% | -15.4% | -39.5% | |
| Q3 2020 | +1.4% | +3.8% | +8.0% | |
| Q2 2020 | -20.2% | -23.0% | -48.8% | |
| Q1 2020 | +0.0% | -5.2% | -24.2% | |
| Q4 2019 | -15.7% | -19.1% | -11.1% | |
| Q3 2019 | -27.5% | -50.6% | -64.7% | |
| Q2 2019 | +4.3% | -1.1% | +43.9% | |
| Q1 2019 | -4.7% | -8.8% | +54.9% | |
| Q4 2018 | -7.1% | -7.9% | +52.8% | |
| Q3 2018 | -4.7% | -17.8% | -9.3% | |
| Q2 2018 | +6.1% | +17.4% | -68.9% | |
| Q1 2018 | -2.3% | -17.3% | +7.3% | |
| Q4 2017 | -3.3% | -1.3% | -5.3% | |
| Q3 2017 | -5.2% | -9.8% | -9.9% | |
| Q2 2017 | +2.2% | -0.6% | +6.7% | |
| Q1 2017 | -1.2% | -1.2% | +0.0% | |
| Q4 2016 | +1.1% | -9.0% | +0.0% | |
| Q3 2016 | -3.7% | -9.4% | -23.8% | |
| Q2 2016 | +7.1% | +86.4% | +82.8% | |
| Q1 2016 | +31.5% | — | — | |
| Q4 2015 | +8.9% | — | — | |
| Q3 2015 | -16.6% | — | — | |
| Q2 2015 | +3.0% | — | — | |
| Q1 2015 | -2.5% | — | — | |
| Q4 2014 | +4.2% | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro